Pharmacology of Sevoflurane

Introduction/Overview

Sevoflurane represents a cornerstone agent in modern inhalational anesthesia, belonging to the class of halogenated ethers. Its introduction marked a significant advancement in anesthetic practice due to its favorable pharmacokinetic and pharmacodynamic profile, particularly its low blood-gas solubility and non-pungent odor. This volatile liquid anesthetic is administered via a calibrated vaporizer as part of a balanced anesthetic technique, providing hypnosis, amnesia, and immobility while allowing for rapid titration of anesthetic depth. Its clinical importance is underscored by its widespread use across diverse patient populations, from pediatric induction to maintenance of anesthesia in complex adult surgeries.

The clinical relevance of sevoflurane extends beyond its primary role as an anesthetic. Its properties facilitate rapid induction and emergence, which may contribute to improved operating room efficiency and potentially enhance patient recovery profiles. Furthermore, its hemodynamic profile and minimal metabolism have established it as a preferred agent in patients with specific comorbidities. Understanding its pharmacology is therefore essential for the safe and effective practice of anesthesiology and critical care medicine.

Learning Objectives

• Describe the chemical classification of sevoflurane and its position among other inhaled anesthetics.
• Explain the proposed molecular and cellular mechanisms of action underlying sevoflurane’s anesthetic effects.
• Analyze the pharmacokinetic profile of sevoflurane, including factors influencing its absorption, distribution, metabolism, and elimination.
• Identify the approved clinical indications for sevoflurane and evaluate its role in specific patient populations.
• Recognize the spectrum of adverse effects and drug interactions associated with sevoflurane, and apply this knowledge to mitigate clinical risk.

Classification

Sevoflurane is systematically classified within the broader category of general anesthetics, specifically as an inhalational or volatile anesthetic. This classification distinguishes it from intravenous agents and defines its primary route of administration. Within the inhalational group, it is a member of the halogenated ether family, sharing structural similarities with other agents like isoflurane and desflurane, but distinct from the older halogenated hydrocarbon, halothane.

Chemical Classification

Chemically, sevoflurane is identified as fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether. Its molecular formula is C₄H₃F₇O, and it has a molecular weight of 200.06 g/mol. The structure consists of an ether linkage (R-O-R’) with extensive fluorination. This fluorination is a critical determinant of its physical and pharmacological properties. The molecule is a clear, colorless, non-flammable, and non-explosive liquid at room temperature with a characteristic mild, non-pungent odor. Its boiling point is 58.6°C, and it possesses a saturated vapor pressure of approximately 160 mm Hg at 20°C. The high degree of fluorination contributes to its low blood-gas partition coefficient of 0.65, a key feature enabling rapid induction and emergence from anesthesia.

Mechanism of Action

The precise mechanism by which sevoflurane, and indeed all general anesthetics, produce the state of unconsciousness, amnesia, immobility, and autonomic stability remains an area of active research. The prevailing theory is the unitary theory of anesthesia, which posits that these agents act by modulating synaptic transmission in the central nervous system, rather than through a single specific receptor. The primary sites of action are neuronal ion channels, with enhancement of inhibitory neurotransmission and suppression of excitatory neurotransmission being central to the anesthetic state.

Molecular and Cellular Mechanisms

At the molecular level, sevoflurane exhibits a promiscuous interaction with multiple ligand-gated and voltage-gated ion channels. Its effects are predominantly mediated through potentiation of inhibitory γ-aminobutyric acid type A (GABA_A) receptors. Sevoflurane binds to specific sites on these pentameric chloride channels, distinct from the binding sites for benzodiazepines or barbiturates, leading to an increased duration of chloride channel opening in response to GABA. This enhanced chloride influx hyperpolarizes the neuronal membrane, reducing neuronal excitability and firing rates.

Concurrently, sevoflurane inhibits excitatory neurotransmission. It acts as a non-competitive antagonist at N-methyl-D-aspartate (NMDA) glutamate receptors, reducing calcium influx. It also inhibits neuronal nicotinic acetylcholine receptors and modulates various subtypes of voltage-gated sodium, potassium, and calcium channels. These combined actions depress excitatory synaptic transmission, particularly in areas critical for consciousness and memory formation, such as the thalamus, hippocampus, and cerebral cortex.

The immobility produced in response to a noxious stimulus (a key component of the anesthetic state measured by Minimum Alveolar Concentration or MAC) is primarily mediated by actions on the spinal cord, involving depression of motor neuron excitability and modulation of polysynaptic reflexes.

Receptor Interactions and Signal Transduction

Beyond direct ion channel modulation, sevoflurane may influence intracellular second messenger systems. Effects on G-protein coupled receptor signaling and protein kinase pathways have been documented, though their clinical significance is less clear. The net result of these multifaceted interactions is a dose-dependent, reversible depression of central nervous system function. The concept of MAC, defined as the minimum alveolar concentration of anesthetic at 1 atmosphere that prevents movement in 50% of subjects in response to a standardized surgical stimulus, provides a quantitative measure of anesthetic potency. The MAC of sevoflurane in a 40-year-old adult is approximately 2.0%, which is influenced by factors such as age, body temperature, and concomitant drug use.

Pharmacokinetics

The pharmacokinetics of inhaled anesthetics like sevoflurane are uniquely described by the principles of uptake and distribution from the lungs, as the alveolar partial pressure (P_A) drives the partial pressure in the blood (P_a) and ultimately in the brain (P_br). The speed of induction and recovery is largely determined by the anesthetic’s solubility in blood and tissues.

Absorption and Uptake

Administration is exclusively via inhalation. Sevoflurane is delivered as a vapor, mixed with carrier gases (oxygen, nitrous oxide, air), through a precision vaporizer. Absorption occurs across the alveolar-capillary membrane in the lungs. The rate of rise of alveolar concentration (F_A) toward the inspired concentration (F_I) is governed by several factors: alveolar ventilation, cardiac output, and the blood-gas partition coefficient (λ_b/g). Sevoflurane’s low blood-gas partition coefficient of 0.65 means it has low solubility in blood. Consequently, the alveolar concentration rises rapidly, leading to a swift increase in arterial partial pressure and a fast onset of action. This property makes it particularly suitable for inhalational induction.

Distribution

Once in the arterial blood, sevoflurane is distributed to various tissues. The rate of distribution to a tissue group depends on its blood flow and the tissue-blood partition coefficient (λ_t/b). The vessel-rich group (brain, heart, liver, kidneys), which receives a high proportion of cardiac output, equilibrates rapidly. Muscle and skin (the muscle group) equilibrate more slowly, and fat (the vessel-poor group) equilibrates very slowly due to high solubility but low blood flow. The brain-blood partition coefficient for sevoflurane is approximately 1.7, facilitating rapid equilibration between arterial blood and the brain, the primary site of action.

Metabolism

Sevoflurane undergoes biotransformation primarily in the liver via the cytochrome P450 system, specifically the CYP2E1 isoenzyme. The extent of metabolism is relatively low, with approximately 3-5% of the absorbed dose metabolized. The primary metabolic pathway involves oxidative defluorination, yielding inorganic fluoride (F^–) and hexafluoroisopropanol (HFIP). HFIP is rapidly conjugated with glucuronic acid and excreted renally. The production of fluoride ions was initially a concern due to the experience with methoxyflurane, which caused high-output renal failure from fluoride nephrotoxicity. However, the peak fluoride levels produced by sevoflurane, even after prolonged administration, typically remain below the putative nephrotoxic threshold of 50 µM, and clinically significant renal impairment from fluoride is considered rare.

A unique aspect of sevoflurane metabolism involves its interaction with carbon dioxide (CO₂) absorbents, particularly desiccated soda lime or Baralyme®. Under conditions of high temperature and low absorbent water content, sevoflurane can degrade to form Compound A (fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether). Compound A is a dose-dependent nephrotoxin in rats, but its clinical significance in humans remains controversial, with no definitive evidence of renal injury under conditions of normal clinical practice with fresh gas flows above 1 L/min.

Excretion and Elimination

The major route of elimination is exhalation of the unchanged parent compound through the lungs. This process is the reverse of uptake; elimination is rapid due to the same low solubility that favored rapid induction. A small fraction is eliminated as metabolites in urine. The context-sensitive half-time, a more clinically relevant measure of recovery than elimination half-life, is very short for sevoflurane, contributing to fast emergence from anesthesia even after prolonged administration.

Pharmacokinetic Parameters and Dosing Considerations

Dosing is titrated to effect using the vaporizer’s dial, which delivers a specific volume percent (%) of sevoflurane vapor. Induction doses typically range from 4-8% in oxygen or oxygen/nitrous oxide mixtures. Maintenance doses usually range from 1-3%, adjusted based on patient factors (age, comorbidities), surgical stimulus, and use of adjunctive agents (opioids, sedatives). MAC values serve as a guide: MAC_awake (0.5-0.7%) for awakening, and MAC_BAR (≈2.5%) for blockade of autonomic responses. The low solubility allows for rapid changes in anesthetic depth with adjustments to the inspired concentration.

Therapeutic Uses/Clinical Applications

Sevoflurane is approved for the induction and maintenance of general anesthesia in inpatient and outpatient surgical procedures for adult and pediatric patients. Its applications are broad, guided by its pharmacokinetic advantages and safety profile.

Approved Indications

• Induction of General Anesthesia: Its non-pungent odor and lack of airway irritation make it the inhalational agent of choice for inhalational induction, especially in pediatric patients where intravenous access may not be established. It is also valuable in adults with difficult intravenous access or for specific techniques like deep extubation.
• Maintenance of General Anesthesia: It is widely used for maintenance during a vast array of surgical procedures, from short outpatient cases to prolonged major surgeries. Its rapid adjustability and stable hemodynamic profile are advantageous.
• Sedation in Critical Care: While not a primary sedative, sevoflurane delivered via specialized vaporizers (e.g., the AnaConDa® system) has been used for long-term sedation in mechanically ventilated intensive care unit patients, offering potential benefits of rapid wake-up for neurological assessment.

Common Off-Label Uses

• Treatment of Status Asthmaticus: In severe, refractory bronchospasm, very low concentrations of sevoflurane have been used for its potent bronchodilatory effects, which are mediated by direct relaxation of bronchial smooth muscle and possibly modulation of autonomic tone.
• Procedural Sedation: Occasionally used for brief, painful procedures in controlled settings.
• Neuroanesthesia: Its effects on cerebral metabolic rate, cerebral blood flow, and intracranial pressure are favorable compared to some older agents, making it a consideration in neurosurgical procedures, though its use is balanced against the potential for epileptiform activity.

Adverse Effects

Like all potent pharmacological agents, sevoflurane is associated with a range of adverse effects, most of which are dose-dependent and manageable with appropriate clinical monitoring and intervention.

Common Side Effects

• Cardiovascular: Dose-dependent depression of myocardial contractility and systemic vascular resistance can lead to hypotension. It may also cause a mild increase in heart rate. These effects are generally less pronounced than with older agents like halothane or isoflurane.
• Respiratory: Produces a dose-dependent depression of ventilation, reducing tidal volume and increasing respiratory rate, though minute ventilation may still fall. It is a potent bronchodilator.
• Central Nervous System: Can produce excitatory phenomena during induction (e.g., agitation, coughing, breath-holding) and emergence (e.g., delirium, especially in children and the elderly). It has been associated with epileptiform EEG activity, particularly at high concentrations and with hyperventilation, though overt clinical seizures are rare.
• Postoperative Nausea and Vomiting (PONV): Like other volatile anesthetics, it is an independent risk factor for PONV.

Serious/Rare Adverse Reactions

• Malignant Hyperthermia (MH): Sevoflurane is a potent triggering agent for this rare, life-threatening pharmacogenetic disorder of skeletal muscle calcium regulation. Susceptible individuals (often with mutations in the RYR1 gene) develop a hypermetabolic crisis characterized by hypercapnia, tachycardia, hyperthermia, rigidity, and acidosis upon exposure.
• Hepatotoxicity: Cases of postoperative hepatic dysfunction, ranging from mild transaminitis to fulminant hepatic necrosis, have been reported. The mechanism may involve immune-mediated hypersensitivity (“halothane hepatitis”-like) or direct toxicity from reactive metabolites. The incidence is considered significantly lower than with halothane.
• Nephrotoxicity: Concerns primarily revolve around two pathways: fluoride ion production and Compound A generation. As noted, clinically significant fluoride nephrotoxicity is exceedingly rare. The risk from Compound A appears minimal with the use of modern CO₂ absorbents and fresh gas flows above 1-2 L/min.
• QTc Prolongation: May modestly prolong the QTc interval on the electrocardiogram, a consideration in patients with congenital long QT syndrome or those on other QT-prolonging drugs.

Black Box Warnings

Sevoflurane does not currently carry any FDA-mandated black box warnings. However, its product labeling contains strong warnings regarding its role as a trigger for malignant hyperthermia and the potential for renal injury associated with Compound A exposure under low-flow anesthesia conditions.

Drug Interactions

The pharmacological effects of sevoflurane are frequently modified by concomitant drug administration, necessitating careful dose adjustment and vigilant monitoring.

Major Drug-Drug Interactions

• Non-Depolarizing Neuromuscular Blocking Agents (NMBAs): Sevoflurane potentiates the effects of both aminosteroid (e.g., rocuronium, vecuronium) and benzylisoquinolinium (e.g., atracurium, cisatracurium) NMBAs. This synergism reduces the required dose of the NMBA and prolongs its duration of action. The mechanism involves enhanced neuromuscular blockade at the post-junctional membrane.
• Opioids and Other CNS Depressants: Additive or synergistic depression of central nervous system and cardiorespiratory function occurs with benzodiazepines, propofol, barbiturates, and opioids. This interaction allows for a reduction in the required concentration of sevoflurane (MAC reduction) but increases the risk of hypotension and respiratory depression.
• Sympathomimetic Agents: The combination with catecholamines like epinephrine may increase the risk of cardiac arrhythmias, particularly ventricular ectopy, though this risk is lower with sevoflurane than with older agents such as halothane.
• Drugs Affecting Hepatic Enzymes: Agents that induce CYP2E1 (e.g., chronic ethanol use, isoniazid) may theoretically increase the rate of sevoflurane metabolism and fluoride ion production, though the clinical impact is likely negligible.
• Other QT-Prolonging Drugs: Concomitant use with agents such as certain antiarrhythmics (sotalol, amiodarone), antipsychotics, and antibiotics (macrolides, fluoroquinolones) may have additive effects on cardiac repolarization, potentially increasing arrhythmia risk.

Contraindications

• Known or Suspected Susceptibility to Malignant Hyperthermia: Absolute contraindication. Personal or family history of MH, or associated conditions like central core disease.
• Known Hypersensitivity: Contraindicated in patients with a history of hypersensitivity reaction to sevoflurane or other halogenated agents, especially if associated with severe hepatic injury.
• Intracranial Hypertension: Relative contraindication. While sevoflurane can increase cerebral blood flow and intracranial pressure (ICP), this effect is modest and can be mitigated by hyperventilation. Its use in patients with significantly elevated ICP requires careful evaluation.

Special Considerations

The safe use of sevoflurane requires adaptation of its administration to specific patient physiological states and pathologies.

Pregnancy and Lactation

Pregnancy: Sevoflurane is classified as FDA Pregnancy Category B. Animal reproduction studies have not demonstrated fetal harm at clinically relevant doses, but no adequate, well-controlled studies exist in pregnant women. It crosses the placenta readily. Its use during pregnancy, particularly in the first trimester, should be reserved for situations where the benefit clearly justifies the potential risk to the fetus. It is commonly used for cesarean deliveries, where rapid induction and uterine relaxation may be beneficial, though the latter can increase blood loss.

Lactation: It is not known whether sevoflurane is excreted in human milk. However, due to its rapid pulmonary elimination and low solubility, the amount present in breast milk is likely to be negligible. A common clinical practice is to allow mothers to breastfeed once they are fully alert and recovered from anesthesia.

Pediatric Considerations

Sevoflurane is extensively used in pediatric anesthesia. The MAC in infants (3-6 months) is highest, approximately 3.3%, and decreases with age. Its non-pungency makes it ideal for inhalational induction. A significant concern is the higher incidence of emergence agitation or delirium in children, characterized by inconsolability, disorientation, and non-purposeful movement. Strategies to reduce this include adequate analgesia, a calm emergence environment, and pre- or intra-operative use of agents like dexmedetomidine or fentanyl. The potential for epileptiform EEG activity is also a consideration, though clinical seizures are uncommon.

Geriatric Considerations

Age-related physiological changes significantly alter sevoflurane pharmacokinetics and pharmacodynamics. MAC decreases linearly with age, approximately 6% per decade, such that the MAC for an 80-year-old is roughly 1.0%. Reduced cardiac output and increased body fat composition alter uptake and distribution. Enhanced sensitivity of the central nervous and cardiovascular systems necessitates the use of lower concentrations to achieve the same anesthetic depth, with a heightened risk of hypotension, postoperative cognitive dysfunction, and delirium. Dosing must be carefully titrated, often utilizing processed EEG monitors (e.g., BIS) to guide depth.

Renal and Hepatic Impairment

Renal Impairment: Patients with pre-existing renal disease may be more susceptible to further renal insult. While the risk from fluoride is considered minimal, it may be prudent to avoid prolonged, low-flow sevoflurane anesthesia in patients with severe renal impairment (e.g., creatinine clearance < 30 mL/min) due to the theoretical Compound A risk. Maintaining adequate hydration and renal perfusion is paramount.

Hepatic Impairment: As metabolism occurs in the liver, severe hepatic impairment could potentially alter the pharmacokinetic profile, though the clinical impact is likely minor given the low extent of metabolism. The primary concern is the potential for worsening pre-existing hepatic encephalopathy due to CNS depression and the rare risk of drug-induced hepatotoxicity. Baseline and postoperative liver function tests may be warranted in patients with significant liver disease.

Summary/Key Points

• Sevoflurane is a fluorinated methyl isopropyl ether used for the induction and maintenance of general anesthesia, valued for its low blood-gas solubility (0.65) and non-pungent odor.
• Its mechanism of action involves potentiation of GABA_A receptor-mediated inhibition and suppression of excitatory neurotransmission (e.g., NMDA receptors) across multiple CNS sites.
• Pharmacokinetics are characterized by rapid alveolar uptake and elimination due to low solubility, facilitating quick induction and emergence. Approximately 3-5% is metabolized by CYP2E1 to inorganic fluoride and hexafluoroisopropanol.
• Primary clinical uses include inhalational induction (especially in pediatrics) and maintenance for a wide range of surgical procedures. Off-label uses include sedation in ICU and treatment of refractory bronchospasm.
• Common adverse effects include dose-dependent hypotension, respiratory depression, and postoperative nausea and vomiting. Serious risks include triggering malignant hyperthermia and rare hepatotoxicity.
• Significant drug interactions include potentiation of neuromuscular blocking agents and additive CNS depression with opioids and sedatives. It is contraindicated in known MH-susceptible individuals.
• Special considerations: MAC decreases with age; pediatric patients are prone to emergence agitation; lower doses are required in the elderly; and use in severe renal/hepatic impairment requires caution.

Clinical Pearls

• For inhalational induction in adults or children, start with 4-8% sevoflurane in 100% oxygen, increasing gradually to avoid excitatory phenomena.
• To minimize the risk of Compound A formation, maintain fresh gas flows above 1 L/min, especially during prolonged anesthesia or with desiccated CO₂ absorbents.
• Emergence agitation in children can often be mitigated by ensuring profound analgesia prior to emergence and considering a single small dose of propofol or dexmedetomidine.
• In patients showing signs of severe bronchospasm under anesthesia, consider adding a low concentration (e.g., 1-2%) of sevoflurane to the gas mixture for its bronchodilatory effects.
• Always have a supply of dantrolene readily available whenever volatile anesthetics, including sevoflurane, are used, due to the risk of malignant hyperthermia.

References

1. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
7. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
8. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.